Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin-conjugating enzyme E2 H (UBE2H) is a member of the E2 ubiquitin-conjugating enzyme family responsible for transferring ubiquitin from E1 activating enzymes to substrate proteins, in processes mediated and regulated by E3 ubiquitin ligases such as the GID/CTLH complex[1][3][5][6]. This transfer is critical for tagging proteins for proteasomal degradation, thereby regulating protein turnover, signaling, and homeostasis in the cell[5]. UBE2H demonstrates specificity for certain polyubiquitin linkage types, such as Lys-11 and Lys-48 chains, and interacts with core components of the CTLH E3 ligase complex[1][3]. Recent structural studies show that multisite phosphorylation of UBE2H is crucial for selective pairing with the GID/CTLH complex, impacting catalytic efficiency and biological function[6]. The human UBE2H protein is highly conserved across vertebrates and exhibits distinct isoforms arising from alternative splicing[5]. Dysfunction of ubiquitin-conjugating enzymes is associated with various diseases, and UBE2H and its complexes have roles in cancer and metabolic regulation[6]. As of now, UBE2H itself is not a known direct drug target, but it is preparatory for therapeutic strategies aiming to modulate the ubiquitin-proteasome system.
Catalytic transfer of ubiquitin from E1 enzyme to substrate proteins, generally in concert with E3 ligases such as GID/CTLH. Facilitates polyubiquitin chain formation (e.g., Lys-11 and Lys-48-linked chains). Requires phosphorylation-dependent multivalent interactions for selectivity in the GID/CTLH complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin-conjugating enzyme E2 H (UBE2H).